Primary tumor response to enfortumab vedotin with/without pembrolizumab in patients with upper tract urothelial cancer. Upstaging and risk migration with blue light cystoscopy for non–muscle-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback